Data in early breast cancer recurrence point to larger market for Lilly’s Verzenio

The positive Phase III readout of Lilly’s Verzenio in early breast cancer opens a path to a new market for the CDK4 and CDK6 inhibitor, one that was recently made clearer by the failure of Pfizer’s CDK4/6 inhibitor Ibrance in a pivotal study in the indication.

Eli Lilly and Co. (NYSE:LLY) rose $22.19 (16%) to $163.71, gaining about $21 billion in market cap, after revealing Tuesday that a preplanned interim analysis found Verzenio abemaciclib led to a statistically significant improvement in invasive disease-free survival (IDFS) in the monarchE trial. Detailed data weren’t disclosed...